BioCentury
ARTICLE | Company News

Pieris, Aska deal

March 3, 2017 5:21 AM UTC

Pieris granted Aska an exclusive option to develop and commercialize PRS-080 in Japan, South Korea and undisclosed other Asian markets outside of China. Pieris will receive $2.8 million up front. If the option is exercised, Pieris will be eligible for more than $80 million in fees and milestones related to the development and commercialization of the candidate in Japan. Pieris is also eligible for additional undisclosed milestone payments, plus tiered royalties up to the high teens. ...